Avalo Therapeutics (AVTX) Current Assets (2014 - 2026)

Avalo Therapeutics has reported Current Assets for 13 years, with the latest figure at $88.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 30.03% year-over-year to $88.8 million; the trailing twelve-month figure through Mar 2026 stood at $88.8 million (down 30.03% YoY), and the FY2025 full-year result was $105.3 million, down 24.19% from the prior year.
• Current Assets for Q1 2026 stood at $88.8 million, down from $105.3 million in the prior quarter.
• The five-year high for Current Assets was $138.9 million in Q4 2024, with the low at $7.5 million in Q2 2023.
• Historically, Current Assets has averaged $66.2 million across 5 years, with a median of $86.1 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets plunged 74.74% — and 2024, when it jumped 1554.44%.
• Avalo Therapeutics' Current Assets stood at $16.4 million in 2022, then sank by 48.86% to $8.4 million in 2023, then jumped by 1554.44% to $138.9 million in 2024, then fell by 24.19% to $105.3 million in 2025, then declined by 15.63% to $88.8 million in 2026.
• The last three Current Assets figures came in at $88.8 million (Q1 2026), $105.3 million (Q4 2025), and $113.8 million (Q3 2025), per Business Quant data.